Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prostate-specific antigen measurement Clear all
Not listed No phase listed Observational

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

NCT00850941
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
3
States / cities
Albuquerque, New Mexico • Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

NCT04530552
View directory record Official record
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01145508
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Docetaxel, Laboratory Biomarker Analysis, Prednisone, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Rilimogene Galvacirepvec
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
14
States / cities
Jacksonville, Florida • Chicago, Illinois • Highland Park, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Not applicable Interventional

A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA

NCT03087903
View directory record Official record
Conditions
Prostate Cancer
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Smart Prostate Specific Antigen (PSA) Screening Study

NCT04782713
View directory record Official record
Conditions
PSA, Prostate Cancer
Interventions
Completing surveys
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Not applicable Interventional

Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men

NCT00761124
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intervention Session, Printed Material
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 70 Years · Male only
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 26, 2026, 1:48 AM EDT
Not listed Not applicable Interventional

MyProstateScore Equivalency With and Without DRE

NCT05700370
View directory record Official record
Conditions
Prostate Cancer
Interventions
MyProstateScore
Diagnostic Test
Lead sponsor
LynxDx
Industry
Eligibility
45 Years and older · Male only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 26, 2026, 1:48 AM EDT
Not listed Phase 2 Interventional

Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

NCT03579654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proscavax
Biological
Lead sponsor
OncBioMune Pharmaceuticals
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 26, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional Results available

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

NCT01420861
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 26, 2026, 1:48 AM EDT
Terminated No phase listed Observational

Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy

NCT05872503
View directory record Official record
Conditions
Prostate Specific Antigens, Positive Digital Rectal Examination, Strong Family History of Prostate Cancer, Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years to 120 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 26, 2026, 1:48 AM EDT
Not yet recruiting Phase 2 Interventional

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Digoxin for Recurrent Prostate Cancer

NCT01162135
View directory record Official record
Conditions
Prostate Cancer
Interventions
Digoxin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

NCT00003871
View directory record Official record
Conditions
Prostate Cancer
Interventions
fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Indianapolis, Indiana • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

NCT00001266
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Suramin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

NCT01046916
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Portland, Oregon • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

NCT00450463
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

NCT00901342
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Park Ridge, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 26, 2026, 1:48 AM EDT
Completed No phase listed Observational

Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

NCT00035217
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

NCT00005039
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 26, 2026, 1:48 AM EDT
Not listed Phase 2 Interventional

Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer

NCT00731848
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate liquid extract
Dietary Supplement
Lead sponsor
Roll International Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 26, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00667862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 26, 2026, 1:48 AM EDT